Juq-470 [verified] Jun 2026

Got a project that already uses the JUQ‑470? Drop a comment below—let’s share real‑world tips and tricks!

The JUQ-470 offers numerous benefits and advantages, including: JUQ-470

| Model | Dose (mg/kg) | Schedule | Tumor growth inhibition (TGI) | Key observations | |-------|--------------|----------|------------------------------|-------------------| | | 30 | q.d. (once daily) oral | 85 % | Significant tumor shrinkage; complete regressions in 2/6 mice. | | VEGF‑overexpressing colon carcinoma (HT‑29 xenograft) | 25 | q.d. oral | 78 % | Reduced microvessel density (CD31 IHC) by 65 %. | | Patient‑derived xenograft (PDX) from FGFR1‑amplified breast cancer | 40 | q.d. oral | 92 % | Durable response, delayed tumor re‑growth for >30 days post‑treatment. | | Safety/toxicity (rat 28‑day repeat dose) | 10‑100 mg/kg | q.d. oral | No lethal toxicity; observed reversible elevation of ALT/AST at ≥50 mg/kg. | No significant weight loss; mild gastrointestinal irritation noted. | Got a project that already uses the JUQ‑470